Dr. Thomas Adam Abrams, MD

Dr. Abrams practices at Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute.

Dr. Abrams' NPI, 1184693947, was assigned on March 15, 2006. Dr. Abrams graduated from Sidney Kimmel Medical College in 2000. Dr. Abrams holds Massachusetts license 228795.

Dr. Abrams' primary practice is Dana-Farber Cancer Institute, at 450 Brookline Avenue, Boston, MA 02115.

Dr. Abrams' primary practice is Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute. Dr. Abrams is also affiliated with Brigham and Women's Hospital. The medical group on file is Binney Medical Group. Dmand AI also links Dr. Abrams to 2 more hospitals, 1 group practice or clinic, 1 home health agency and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Abrams practices, 7 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Abrams' primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Abrams is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Abrams' licenses on file in 4 states: Massachusetts, Florida, New Hampshire and Michigan.

Dmand AI lists breast cancer and colorectal cancer among the conditions Dr. Abrams treats.

CMS data shows 564 Medicare services from Dr. Abrams across 6 procedure codes in 2024, for 239 Medicare patients. Medicare paid $45,192 for them.

CMS counts 239 Medicare patients who saw Dr. Abrams in 2024. The largest group is 65 to 74, with 114 patients. 75% of them have high blood pressure, and 68% have high cholesterol. 18% are also on Medicaid. Their average risk score is 2.34, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Abrams' median patient age at 68, with 44% women.

In 2024, Dr. Abrams wrote 481 Medicare Part D claims for 71 patients. 72% of them were for generic drugs. CMS names the drug for 257 of them, across 14 drugs with 11 or more claims each, at $301,455 in total drug cost. In 2023, CMS named 455 claims across 20 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Abrams for performance year 2024, reported as part of a group. Dr. Abrams accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Abrams as offering telehealth.

Dmand AI links 70 papers to Dr. Abrams, published from 2008 to 2025. 2020 was the busiest year, with 5. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Liver Neoplasms and Carcinoma, Hepatocellular. Dr. Abrams has published most often in Cancer. Dr. Abrams' most frequent co-authors are Lawrence Scott Blaszkowsky, MD, Kimmie Ng, MD and Jennifer Ang Chan, MD.

Dmand AI links Dr. Abrams to 6 clinical trials, 4 of them phase 2 studies. Conditions studied include Liver Neoplasms, Liver Diseases and Bile Duct Neoplasms. Massachusetts General Hospital sponsors the most, 4.

CMS Open Payments shows 189 general payments to Dr. Abrams from 15 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 53% of the total. Eli Lilly and Company paid the most, $178,310. It also lists 4 research payments totaling $12,723 from 2016 to 2022.

Dr. Abrams serves on National Comprehensive Cancer Network (NCCN) Hepatobiliary Cancers Guidelines Committee.

Dr. Abrams graduated from Sidney Kimmel Medical College in 2000. Dr. Abrams is a member of ASCO.

Dr. Abrams is in network with 12 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.